Related Experiment Video
Updated: Jul 10, 2025
09:43
Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
2.9K
Neuropeptide Y, a potential marker for lupus, promotes lupus development
Da-Cheng Wang1, Wang-Dong Xu1, Yang-Yang Tang1
1Department of Evidence-Based Medicine, Southwest Medical University, 1 Xianglin Road, Luzhou, Sichuan 646000, China.
International Immunopharmacology
|November 25, 2023
Summary
Neuropeptide Y (NPY) is elevated in systemic lupus erythematosus (SLE) patients and may promote disease development. Blocking the NPY-Y1 receptor in mice reduced lupus indicators, suggesting NPY as a potential therapeutic target.
Area of Science:
- Immunology
- Genetics
- Biochemistry
Background:
- Neuropeptide Y (NPY) involvement in systemic lupus erythematosus (SLE) pathogenesis remains unclear.
- The role of NPY in SLE development requires further investigation.
Purpose of the Study:
- To clarify the relationship between NPY serum levels, NPY genetic mutations, and SLE pathogenesis.
- To elucidate the role of NPY in the development of SLE.
Main Methods:
- Serum NPY, MMP-1, and MMP-8 levels were measured in 460 SLE patients, 472 non-SLE cases, and 500 healthy controls.
- Genotyping of seven NPY single nucleotide polymorphisms (SNPs) was performed using the KASP method.
- Pristane-induced lupus mice were treated with an NPY-Y1 receptor antagonist to evaluate therapeutic effects.
Main Results:
- SLE patients exhibited significantly higher serum NPY concentrations compared to controls.
- Specific NPY SNPs (rs5573, rs16129, rs16147) showed significant frequency differences between SLE cases and healthy controls.
- NPY-Y1 receptor antagonist treatment in lupus mice alleviated organ damage, reduced autoantibody production, and normalized immune cell differentiation.
Conclusions:
- Neuropeptide Y (NPY) may serve as a biomarker for lupus.
- NPY may play a role in the occurrence and development of SLE.
